Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

0
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Category

Show more Refine

For: Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31-41. [PMID: 27932067 PMCID: PMC5476941 DOI: 10.1016/s1470-2045(16)30624-6] [Citation(s) in RCA: 766] [Impact Index Per Article: 95.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 10/01/2016] [Accepted: 10/05/2016] [Indexed: 12/20/2022]

For:	Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31-41. [PMID: 27932067 PMCID: PMC5476941 DOI: 10.1016/s1470-2045(16)30624-6] [Citation(s) in RCA: 766] [Impact Index Per Article: 95.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 10/01/2016] [Accepted: 10/05/2016] [Indexed: 12/20/2022]

No articles found.

(The first 100,000 artilces are displayed in RCA.)